Cargando…
Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026340/ https://www.ncbi.nlm.nih.gov/pubmed/29958537 http://dx.doi.org/10.1186/s12967-018-1552-1 |
| _version_ | 1783336423629258752 |
|---|---|
| author | Liau, Linda M. Ashkan, Keyoumars Tran, David D. Campian, Jian L. Trusheim, John E. Cobbs, Charles S. Heth, Jason A. Salacz, Michael Taylor, Sarah D’Andre, Stacy D. Iwamoto, Fabio M. Dropcho, Edward J. Moshel, Yaron A. Walter, Kevin A. Pillainayagam, Clement P. Aiken, Robert Chaudhary, Rekha Goldlust, Samuel A. Bota, Daniela A. Duic, Paul Grewal, Jai Elinzano, Heinrich Toms, Steven A. Lillehei, Kevin O. Mikkelsen, Tom Walbert, Tobias Abram, Steven R. Brenner, Andrew J. Brem, Steven Ewend, Matthew G. Khagi, Simon Portnow, Jana Kim, Lyndon J. Loudon, William G. Thompson, Reid C. Avigan, David E. Fink, Karen L. Geoffroy, Francois J. Lindhorst, Scott Lutzky, Jose Sloan, Andrew E. Schackert, Gabriele Krex, Dietmar Meisel, Hans-Jorg Wu, Julian Davis, Raphael P. Duma, Christopher Etame, Arnold B. Mathieu, David Kesari, Santosh Piccioni, David Westphal, Manfred Baskin, David S. New, Pamela Z. Lacroix, Michel May, Sven-Axel Pluard, Timothy J. Tse, Victor Green, Richard M. Villano, John L. Pearlman, Michael Petrecca, Kevin Schulder, Michael Taylor, Lynne P. Maida, Anthony E. Prins, Robert M. Cloughesy, Timothy F. Mulholland, Paul Bosch, Marnix L. |
| author_facet | Liau, Linda M. Ashkan, Keyoumars Tran, David D. Campian, Jian L. Trusheim, John E. Cobbs, Charles S. Heth, Jason A. Salacz, Michael Taylor, Sarah D’Andre, Stacy D. Iwamoto, Fabio M. Dropcho, Edward J. Moshel, Yaron A. Walter, Kevin A. Pillainayagam, Clement P. Aiken, Robert Chaudhary, Rekha Goldlust, Samuel A. Bota, Daniela A. Duic, Paul Grewal, Jai Elinzano, Heinrich Toms, Steven A. Lillehei, Kevin O. Mikkelsen, Tom Walbert, Tobias Abram, Steven R. Brenner, Andrew J. Brem, Steven Ewend, Matthew G. Khagi, Simon Portnow, Jana Kim, Lyndon J. Loudon, William G. Thompson, Reid C. Avigan, David E. Fink, Karen L. Geoffroy, Francois J. Lindhorst, Scott Lutzky, Jose Sloan, Andrew E. Schackert, Gabriele Krex, Dietmar Meisel, Hans-Jorg Wu, Julian Davis, Raphael P. Duma, Christopher Etame, Arnold B. Mathieu, David Kesari, Santosh Piccioni, David Westphal, Manfred Baskin, David S. New, Pamela Z. Lacroix, Michel May, Sven-Axel Pluard, Timothy J. Tse, Victor Green, Richard M. Villano, John L. Pearlman, Michael Petrecca, Kevin Schulder, Michael Taylor, Lynne P. Maida, Anthony E. Prins, Robert M. Cloughesy, Timothy F. Mulholland, Paul Bosch, Marnix L. |
| author_sort | Liau, Linda M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6026340 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-60263402018-07-09 Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma Liau, Linda M. Ashkan, Keyoumars Tran, David D. Campian, Jian L. Trusheim, John E. Cobbs, Charles S. Heth, Jason A. Salacz, Michael Taylor, Sarah D’Andre, Stacy D. Iwamoto, Fabio M. Dropcho, Edward J. Moshel, Yaron A. Walter, Kevin A. Pillainayagam, Clement P. Aiken, Robert Chaudhary, Rekha Goldlust, Samuel A. Bota, Daniela A. Duic, Paul Grewal, Jai Elinzano, Heinrich Toms, Steven A. Lillehei, Kevin O. Mikkelsen, Tom Walbert, Tobias Abram, Steven R. Brenner, Andrew J. Brem, Steven Ewend, Matthew G. Khagi, Simon Portnow, Jana Kim, Lyndon J. Loudon, William G. Thompson, Reid C. Avigan, David E. Fink, Karen L. Geoffroy, Francois J. Lindhorst, Scott Lutzky, Jose Sloan, Andrew E. Schackert, Gabriele Krex, Dietmar Meisel, Hans-Jorg Wu, Julian Davis, Raphael P. Duma, Christopher Etame, Arnold B. Mathieu, David Kesari, Santosh Piccioni, David Westphal, Manfred Baskin, David S. New, Pamela Z. Lacroix, Michel May, Sven-Axel Pluard, Timothy J. Tse, Victor Green, Richard M. Villano, John L. Pearlman, Michael Petrecca, Kevin Schulder, Michael Taylor, Lynne P. Maida, Anthony E. Prins, Robert M. Cloughesy, Timothy F. Mulholland, Paul Bosch, Marnix L. J Transl Med Correction BioMed Central 2018-06-29 /pmc/articles/PMC6026340/ /pubmed/29958537 http://dx.doi.org/10.1186/s12967-018-1552-1 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Correction Liau, Linda M. Ashkan, Keyoumars Tran, David D. Campian, Jian L. Trusheim, John E. Cobbs, Charles S. Heth, Jason A. Salacz, Michael Taylor, Sarah D’Andre, Stacy D. Iwamoto, Fabio M. Dropcho, Edward J. Moshel, Yaron A. Walter, Kevin A. Pillainayagam, Clement P. Aiken, Robert Chaudhary, Rekha Goldlust, Samuel A. Bota, Daniela A. Duic, Paul Grewal, Jai Elinzano, Heinrich Toms, Steven A. Lillehei, Kevin O. Mikkelsen, Tom Walbert, Tobias Abram, Steven R. Brenner, Andrew J. Brem, Steven Ewend, Matthew G. Khagi, Simon Portnow, Jana Kim, Lyndon J. Loudon, William G. Thompson, Reid C. Avigan, David E. Fink, Karen L. Geoffroy, Francois J. Lindhorst, Scott Lutzky, Jose Sloan, Andrew E. Schackert, Gabriele Krex, Dietmar Meisel, Hans-Jorg Wu, Julian Davis, Raphael P. Duma, Christopher Etame, Arnold B. Mathieu, David Kesari, Santosh Piccioni, David Westphal, Manfred Baskin, David S. New, Pamela Z. Lacroix, Michel May, Sven-Axel Pluard, Timothy J. Tse, Victor Green, Richard M. Villano, John L. Pearlman, Michael Petrecca, Kevin Schulder, Michael Taylor, Lynne P. Maida, Anthony E. Prins, Robert M. Cloughesy, Timothy F. Mulholland, Paul Bosch, Marnix L. Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma |
| title | Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma |
| title_full | Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma |
| title_fullStr | Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma |
| title_full_unstemmed | Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma |
| title_short | Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma |
| title_sort | correction to: first results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026340/ https://www.ncbi.nlm.nih.gov/pubmed/29958537 http://dx.doi.org/10.1186/s12967-018-1552-1 |
| work_keys_str_mv | AT liaulindam correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT ashkankeyoumars correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT trandavidd correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT campianjianl correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT trusheimjohne correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT cobbscharless correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT hethjasona correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT salaczmichael correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT taylorsarah correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT dandrestacyd correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT iwamotofabiom correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT dropchoedwardj correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT moshelyarona correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT walterkevina correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT pillainayagamclementp correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT aikenrobert correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT chaudharyrekha correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT goldlustsamuela correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT botadanielaa correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT duicpaul correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT grewaljai correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT elinzanoheinrich correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT tomsstevena correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT lilleheikevino correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT mikkelsentom correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT walberttobias correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT abramstevenr correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT brennerandrewj correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT bremsteven correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT ewendmatthewg correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT khagisimon correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT portnowjana correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT kimlyndonj correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT loudonwilliamg correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT thompsonreidc correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT avigandavide correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT finkkarenl correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT geoffroyfrancoisj correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT lindhorstscott correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT lutzkyjose correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT sloanandrewe correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT schackertgabriele correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT krexdietmar correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT meiselhansjorg correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT wujulian correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT davisraphaelp correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT dumachristopher correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT etamearnoldb correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT mathieudavid correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT kesarisantosh correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT piccionidavid correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT westphalmanfred correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT baskindavids correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT newpamelaz correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT lacroixmichel correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT maysvenaxel correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT pluardtimothyj correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT tsevictor correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT greenrichardm correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT villanojohnl correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT pearlmanmichael correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT petreccakevin correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT schuldermichael correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT taylorlynnep correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT maidaanthonye correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT prinsrobertm correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT cloughesytimothyf correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT mulhollandpaul correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma AT boschmarnixl correctiontofirstresultsonsurvivalfromalargephase3clinicaltrialofanautologousdendriticcellvaccineinnewlydiagnosedglioblastoma |